The purpose and objectives of this requirement is to obtain source or sources of currently marketed drugs products for FDA research studies.
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- 75F40120D00032
- Awardee
-
We Pharma, Inc. UEI EWAMVJSFNK29
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Task orders
- 10 $2,558,794 obligated
Award facts
- Opportunity
-
- To provide brand name and/or generic pharmaceuticals to include small molecule and peptide therapeutics, drug-device combination products, and contrast agents. Solicitation · FDASOL1222072 · Posted Aug 4, 2020
- Combined order value
- $2,558,794 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling 27% used
- $9,500,000.00
- Maximum order
- $9,500,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Two Step
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Health and Human Services Food and Drug Administration awarded an indefinite delivery contract to We Pharma, Inc., doing business as WEP Clinical, with a potential value of $9.5 million. The contract has no set-aside designation and is a single-award arrangement to provide currently marketed drug products for FDA research studies from September 2020 through September 2025.
Under this contract, WEP Clinical has received multiple firm fixed price delivery orders to supply pharmaceuticals to the FDA's offices in Silver Spring, Maryland; St. Louis, Missouri; and Morrisville, North Carolina. Delivery orders range in value from $100,000 to $500,000 with periods of performance from December 2021 through January 2023. The drug products will support the FDA's clinical, regulatory science, research, and compliance activities, including studies related to the Generic Drug User Fee Amendments program.
The original solicitation sought sources of currently marketed drug products for FDA research studies, with responses due in August 2020. WEP Clinical was awarded the indefinite delivery contract and subsequent delivery orders to provide the requested pharmaceuticals.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75F40120D00032?
75F40120D00032 was awarded to We Pharma, Inc. by Food and Drug Administration (Department of Health and Human Services) on September 29, 2020.
How much is contract 75F40120D00032 worth?
Orders under 75F40120D00032 have obligated $2,558,794. 75F40120D00032's own ceiling is $9,500,000. A single order can be worth up to $9,500,000.
How many orders have been placed under contract 75F40120D00032?
10 orders have been placed under 75F40120D00032, the latest on September 16, 2025.
Who can order from contract 75F40120D00032?
75F40120D00032 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75F40120D00032 competed?
The extent of competition for 75F40120D00032 was full and open competition. The government received 2 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV